Loading...
Loading...
- iRhythm Technologies Inc IRTC posted an adjusted EPS loss of $(0.63), better than $(0.81) a year ago and the consensus of $(0.83).
- The wearable heart monitor developer recorded sales growth of 21.6% to $103.87 million.
- "Despite the ongoing staffing and capacity challenges, we grew registration volumes by more than 20% in the third quarter, achieving our highest daily registration volumes ever as we exited September," said iRhythm CEO and president Quentin Blackford.
- "However, within the quarter, we also realized softness in returned devices – which impacted our ability to perform our services and realize revenue which muted our growth. We view this as persisting into the fourth quarter. These dynamics, fourth-quarter trends in account staffing and capacity challenges, and Zio AT utilization have led to us reducing our full-year revenue guidance."
- The company held $203.5 million in cash and equivalents as of September 30, 2022.
- Guidance: iRhythm previously set its annual revenue guidance of $415-$420 million. However, its updated guidance projects a reduced range of $407-$411 million, compared to the consensus of $418.72 million.
- Price Action: IRTC shares closed 12.4% lower at $111.00 during after-hours trading on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in